Management of Spironolactone in Mild Acute Kidney Injury

Introduction to Spironolactone Management

The American College of Cardiology recommends continuing spironolactone in patients with mild acute kidney injury (AKI) unless specific thresholds are exceeded, with close monitoring of renal function and potassium levels 1

The American Heart Association suggests continuing spironolactone if creatinine remains ≤2.5 mg/dL in men or ≤2.0 mg/dL in women (or eGFR >30 mL/min/1.73 m²) and potassium remains <5.0 mEq/L 2
The American College of Cardiology recommends continuing spironolactone in heart failure patients with reduced ejection fraction, as oral guideline-directed medical therapy (GDMT) should not be withheld for mild deteriorations in renal function 1

The American College of Cardiology found that spironolactone and beta blockers may be protective in patients with heart failure and worsening renal function 1
Continuation of spironolactone among hospitalized heart failure patients was associated with lower 30-day mortality and heart failure rehospitalization in the COACH study 1
Small to moderate worsening of renal function was not associated with true AKI in patients on oral GDMT 1
Withdrawal of mineralocorticoid receptor antagonists during hospitalization has been associated with worse outcomes 1

The American Heart Association recommends checking potassium and creatinine within 2-3 days after recognizing AKI, then again at 7 days, and monitoring at least monthly for the first 3 months, then every 3 months thereafter 2
Any increase in ACE inhibitor or ARB dosing should trigger a new monitoring cycle 2

The American College of Cardiology notes that while spironolactone carries risks in AKI, these risks must be weighed against mortality benefits in heart failure patients, where continuation during mild renal dysfunction is associated with improved outcomes 1
The key is using absolute threshold values rather than relative changes to guide decisions, combined with intensified monitoring rather than automatic discontinuation 2

The European Society of Cardiology recommends that discontinuing mineralocorticoid receptor antagonists during hospitalization is associated with worse outcomes, and spironolactone discontinuation increases the risk of subsequent adverse events by 2-4 fold, even when stopped for hyperkalemia or low glomerular filtration rate 3
Analysis from the Stockholm SCREAM project showed that stopping an MRA after hyperkalemia reduced recurrent hyperkalemia risk but increased the risk of death or cardiovascular events 3

The European Society of Cardiology suggests that spironolactone should be discontinued in patients with eGFR <30 mL/min/1.73 m² with concurrent hyperkalemia 3